New Delhi: Vaccine maker Novavax has claimed on Monday that the vaccine is more than 90 percent effective against the variants of Corona. This has come to the fore in a large and final phase study conducted in the US and Mexico.
In August last year, American company Novavax had signed a deal with Pune-based Serum Institute of India, under which 200 crore vaccine doses were to be prepared.
These figures regarding the Novavax vaccine have come to the fore at a time when the consumption of the vaccine is increasing continuously in the world. However, the demand for anti-Covid-19 vaccines in the US has decreased. Novavax vaccine is easy to keep and carry. It is expected to play an important role in increasing the supply of vaccines in developing countries.
The company plans to obtain approval for the vaccine for use in the US, Europe and elsewhere by the end of September, and by then it will be able to produce 100 million doses a month. “Many of our initial doses will go to low- and middle-income countries,” the company said.